Sanofi Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001121404
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2024 · 9 positions · Total reported value $174.36M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 37.5% · 6 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -5.4% · vs SPY -7.6% · Prev Value $534.04M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -10.9% · vs SPY -13.1% · Latest Value $629.87M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2024 13F filing, Sanofi disclosed 9 equity positions with a combined reported value of $174.36M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2024 were MGTX ($74.28M), NVAX ($55.32M), INBX ($17.83M). By sector, the heaviest allocations are Health Care 93.2%, Other 6.8%.
Versus the prior quarter, Sanofi opened 6 new positions, trimmed 0 and fully exited 0, a turnover rate of 37.5% of positions.
The largest new positions opened in Q4 2024 were MGTX ($74.28M), NVAX ($55.32M), INBX ($17.83M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2024)
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Sanofi buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-10 | Conversion | Latigo Biotherapeutics, Inc. | 177,978 | — | SEC filing |
| 2026-08-10 | Conversion | Latigo Biotherapeutics, Inc. | 494,800 | — | SEC filing |
| 2026-08-06 | Buy | Attovia Therapeutics, Inc. | 300,000 | $17.00 | SEC filing |
| 2026-08-06 | Conversion | Attovia Therapeutics, Inc. | 782,855 | — | SEC filing |
Fund Profile
Sanofi is an SEC-registered 13F filer. As of Q2 2026 it reported 10 US equity positions with a combined value of $534.04M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).
Portfolio Structure
- 10 positions · $534.04M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: MGTX (MEIRAGTX HLDGS PLC COM) at 30.9%
- Average position size: $53.40M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 2 new, 1 exited
- 8 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
12.20M | $74.28M | 42.60% | New | |
| 2 |
|
6.88M | $55.32M | 31.73% | New | |
| 3 |
|
1.16M | $17.83M | 10.23% | New | |
| 4 |
|
821.92K | $10.88M | 6.24% | New | |
| 5 |
|
1.44M | $8.79M | 5.04% | New | |
| 6 |
|
814.98K | $3.36M | 1.93% | New | |
| 7 |
|
1.92M | $1.83M | 1.05% | New | |
| 8 |
|
443.25K | $1.23M | 0.70% | New | |
| 9 |
|
244.08K | $839.65K | 0.48% | New |
FAQ
What did Sanofi buy in 2024-Q4?
In its 2024-Q4 13F filing, Sanofi reported 9 equity positions worth $174.36M in aggregate; its largest disclosed positions were MGTX ($74.28M), NVAX ($55.32M), INBX ($17.83M).
How large is Sanofi's portfolio?
Sanofi reported $174.36M of long equity holdings across 9 positions as of 2024-Q4. Top-10 holdings account for 100.0% of reported value.
What is Sanofi's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.